A mitochondrial amidoxime-reducing component 1 (mARC1) A168T amino acid substitution does not confer protection from MASH and fibrosis in multiple mouse models of chronic liver disease. This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatohepatitis.